viewDalradian Resources

Dalradian Resources gets thumbs up from Eight Capital after high grade drill results

Meanwhile, nine step-out holes up to 400 metres west of the current resource envelope all encountered mineralization

A gold pour

Broker Eight Capital rated Dalradian Resources Inc (TSE: DNA) a 'buy' after its latest assays from its Curraghinalt gold project in Northern Ireland.

Six underground infill holes averaged 0.86 meters of 30.2 g/t (grams per ton) gold, which was well above the average resource grade of 10.8 g/t of the yellow metal.

Meanwhile, nine step-out holes up to 400 metres west of the current resource envelope all encountered mineralization, averaging 0.69 metres of 34.4 g/t  gold.

Patrick F.N. Anderson, the firm's president and chief, described the step-out results as "exciting", showing "continuity" of the mineralisation.

"A resource update is scheduled for late Q4/17 or Q1/18. This will be followed by an updated feasibility study that will incorporate the positive reconciliation results as well as assays from the 2017 drill program," said analyst Craig Stanley.

Dalradian had $34.6mln in cash and $31mln in working capital as at June 30 this year, notes the analyst.

In July 2017, 9.8 million warrants were exercised for proceeds of $14.7mln.

The broker targets C$1.70 for the shares, against a current price of C$1.38 - up 0.73% on the day.

Quick facts: Dalradian Resources

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Orthocell 'in exciting regulatory phase' as it looks to drive its...

Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the...

13 hours, 35 minutes ago

2 min read